Metabolism. Objectives. Metabolism. 26 July Chapter 28 1

Similar documents
Metabolic Changes of Drugs and Related Organic Compounds. Oxidative Reactions. Shokhan J. Hamid. 3 rd stage/ 1 st course Lecture 6

METABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84

Metabolic Changes of Drugs and Related Organic Compounds

Chapter 4. Drug Biotransformation

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

Patrick, An Introduction to Medicinal Chemistry 5e Chapter 11 Pharmacokinetics and related topics

Pharmacokinetics Metabolism

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

Nonlinear Pharmacokinetics

MEDCHEM 570. First Midterm. January 30, 2015

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Drug Metabolism Phase 2 conjugation reactions. Medicinal chemistry 3 rd stage

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

General pharmacology Lecture(3)

INTRODUCTION TO PHARMACOKINETICS

Metabolic Changes of Drugs and Related Organic Compounds

MODULE No.26: Drug Metabolism

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

PRESCRIBING IN LIVER AND RENAL DISEASE

DRUG ELIMINATION II BILIARY EXCRETION MAMMARY, SALIVARY AND PULMONARY EXCRETION

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Unit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK)

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Pharmacokinetics. Karim Rafaat

General Pharmacology

Effects of Renal Disease on Pharmacokinetics

Drug elimination and Hepatic clearance Chapter 6

Biotransformation of drugs

M O N T H E R A P E D R O R I N G. Dr Tom Hartley UTAS HLS 2014

MEDCHEM 562. First Midterm (KEY) October 15, 2012

CHEMICAL BASIS OF DRUG ACTION

GENERAL PHARMACOLOGY

Name: UFID: PHA Exam 2. Spring 2013

BASIC PHARMACOKINETICS

Effects of Liver Disease on Pharmacokinetics

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Drug Metabolism. Assoc. Prof. Bilgen Basgut 2015

Receptor Sites and Drug Design

Industrial Toxicology

Chapter 9. Biotransformation

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Mechanisms of Drug Action

Effects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

Chapter 10. Carboxylic Acids and Derivatives. Naming Carboxylic Acids and Derivatives. Carboxylic Acids: RCOOH (RCO 2 H)

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Identifying Functional Groups. (Chapter 2 in the Klein text)

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National

NONLINEAR PHARMACOKINETICS: INTRODUCTION

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

Polar bodies are either introduced or unmasked, which results in more polar metabolites Phase I reactions can lead either to activation or

Case Study: Opiates use for Anesthesia & analgesia

The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.

Pharmacokinetics and bioavailability derived from various body fluids. Saliva samples instead of plasma samples

B. Incorrect! Compounds are made more polar, to increase their excretion.

Click to edit Master title style

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

Basic Concepts of TDM

General Pharmacology MCQs

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Name: Class: "Pharmacology NSAIDS (1) Lecture

Pharmacology med term exam

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.

Drug Absorption and Bioavailability

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

TDM. Measurement techniques used to determine cyclosporine level include:

Appendix 5: Hepatic impairment

Toxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine

TDM. Generally, hepatic clearance is determined by three main factors: These three factors can be employed in the following equation:

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Lecture 8: Phase 1 Metabolism

CHAPTER-III PHARMACOKINETIC DRUG INTERACTIONS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE INVESTIGATION OF DRUG INTERACTIONS

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Chapter 20: Carboxylic Acids and Nitriles شیمی آلی 2

Pharmacogenetics and Pharmacokinetics

Bassett Healthcare Clinical Laboratory

Pharmacology Review: Basic Principles. Presented by: A Nelson Avery, MD

Chimica Farmaceutica. Pharmacokinetics and related topics

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition

Prelab 6: Carboxylic Acids

PHARMACOKINETICS: DRUG ABSORPTION, DISTRIBUTION, AND ELIMINATION

CH 3. Lipids CHAPTER SUMMARY

Fundamentals of Organic Chemistry CHEM 109 For Students of Health Colleges Credit hrs.: (2+1)

Benign Prostatic Hyperplasia (BPH) IPT VI Srikanth Kolluru, Ph.D

Biopharmaceutics. Tips Worth Tweeting. Contributor: Sandra Earle

PHA Final Exam Fall 2006

Drug Absorption and Bioavailability

Drug Absorption and Bioavailability

JOHN HARGRAVE. Date of Birth : 31-Oct-1973 Sex : M Collected : 24-Aug BENTONS ROAD MOUNT MARTHA VIC Lab id: UR#:

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Tala Saleh. Abdul Aziz ALShamali. Abdul Aziz ALShamali

1 Introduction COPYRIGHTED MATERIAL. 1.1 Therapeutic w indow Introduction

Transcription:

Metabolism bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect of liver disease on drug elimination Metabolism Elimination by transformation of the drug Usually results in more polar compound easier urinary excretion - less reabsorption usually inactive - hindered transport, doesn t fit receptor verall effect is removal of the drug effect Enzymatic catalysis Liver, intestinal wall, kidney, skin, blood Chapter 28 1

Phase I xidation Reduction Hydrolysis Phase II Conjugation Metabolic Reactions xidation Phase I Addition of oxygen or removal of hydrogen Endoplasmic reticulum Common Reactions include: Alkyl group -> alcohol Aromatic ring -> phenol xidation at S or N xidative dealkylation Monoamineoxidase Alcohol dehydrogenase Alkyl Group > Alcohol e.g. phenobarbitone CH 2 CH 3 CH CH 3 H Chapter 28 2

Aromatic Ring > Phenol e.g. phenytoin H xidation at S or N e.g. chlorpromazine S S xidative Dealkylation e.g. phenacetin H CH 2 CH 3 H CH 3 H + H CH 3 Chapter 28 3

Monoamine oxidase e.g. 5-hydroxytryptamine CH 2 CH 2 NH 2 CH 2 CH + NH 3 Alcohol Dehydrogenase CH 2 CH 2 H CH 2 CH Reduction Phase I Addition of a hydrogen or removal of oxygen azo (-N=N-) or nitro group (-N 2 ) --> amine (-NH 2 ) Chapter 28 4

Hydrolysis Phase I Addition of water In blood (esterases) and liver Ester -> Alcohol and Acid e.g. aspirin to salicylic acid R C CH 3 RH + CH 3 CH Amide -> Amine and Acid e.g. procainamide R N C CH 3 R NH 2 + CH 3 CH Chapter 28 5

Conjugation Phase II Addition of a molecule in the body May be preceded by a Phase I process Glucuronidation In the liver Aliphatic alcohols and phenols e.g. bilirubin, thyroxine, hydroxylated morphine Conjugation Acylation Especially acetylation e.g. sulfonamide Glycine addition e.g. nicotinic acid Sulfation e.g. morphine, paracetamol (acetaminophen) Metabolism More polar compounds e.g. C-H -> C-H e.g. addition of acetyl or sulfate group Generally more water soluble and faster urinary elimination Chapter 28 6

Insoluble Metabolites Metabolites can be less water soluble e.g. Acetyl metabolites of some sulfonamides Resulted in crystalluria after precipitation in tubules Remember all that water reabsorption Triple sulfas Development of sulfonamides with soluble metabolites CHCH 2 CH 2 N(CH 3 ) 2 CHCH 2 CH 2 NHCH 3 Active Metabolites or Pro-Drugs? Amitriptyline to Nortriptyline Codeine to Morphine Primidone to Phenobarbital C 6 H 5 C 2 H 5 H N NH C 6 H 5 C 2 H 5 H N NH CH 3 H H H H H NCH 3 NCH 3 Induction of Metabolism Increase in Enzyme Activity Phenobarbitone induces it s own metabolism and that of other drugs phenytoin, warfarin Carbamazepine induces it s own metabolism - over 4-5 days t 1/2 from 36 to 21 hr Cigarette smoking induces drug metabolism e.g. theophylline t 1/2 4 hr vs. 7 hr Chapter 28 7

Inhibition of Drug Metabolism competitive inhibition Examples warfarin inhibits tolbutamide, phenytoin phenylbutazine inhibits warfarin cimetidine inhibits warfarin Dose adjustment necessary Systemic Clearance with First rder Kinetics single dose CL = F Dose AUC = 0.693 V area t 1/2 multiple dose (at Steady State) CL = k0 F Dose ss = Cp Cp τ Venous Equilibration Model for organ (liver) clearance Chapter 28 8

Venous Equilibration Model Measuring drug concentration entering and leaving liver rgan Clearance= Q L ( Ca Cv) = Q Ca L E where Q L is liver blood flow and E is the extraction ratio Extraction Ratio Values from 0 to 1 Fraction Removed by Liver in one Pass High Value of E means high clearance by the liver very little unmetabolized gets through unchanged Low Value of E means little metabolism CL L and E measures of extent of metabolism Parameters of the Model Total hepatic blood flow, Q Fraction unbound, fu Free intrinsic clearance, CL int clearance from liver plasma water no flow or binding constraints saturable since enzyme mediated Chapter 28 9

The Mathematical Model fu CL CL = Q int Q + fu CL int total ( ) = Q CL int fu CL with E= int Q + fu CL int CL = Q E total Q + CL int Can consider effect of each parameter on overall hepatic clearance high fu CL int value Flow Limited Drugs ( ) total High fu CL int = CL int fu CL int >> Q CL = Q fu CL int = Q fu CL int thus CL is flow limited (equal to Q) independent of changes in fu or CL int e.g. lidocaine, propranolol, morphine Capacity Limited Drugs low fu CL int value ( ) total Low fu CL int = CL int fu CL int << Q CL = Q fu CL int total = fu CL Q int = CL int thus CL is determined by intrinsic clearance independent of changes in Q e.g. phenytoin, warfarin, quinidine Chapter 28 10

ther Drugs fu CL int Q capacity limited - binding insensitive all three parameters important e.g. theophylline, antipyrine Systemic Availability nce the drug is absorbed across the GI tract membrane the drug must get through the liver The extent of the first-pass metabolism can be determined from the extraction ratio, E Fmax = 1 - E e.g. morphine P... 30 mg cf. IV 5 mg Liver Disease Systemic Availability A small change in E may have a large effect on F e.g. E = 0.95 to 0.90 causes F to double In chronic liver disease porta-systemic shunt may reduce First-Pass effect High clearance drugs may be well absorbed after P.. dosage e.g. morphine 30 mg P.. may be similar to 30 mg I.V. Chapter 28 11

bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect of liver disease on drug elimination Chapter 28 12